Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed … [Read More...] about FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed … [Read More...] about FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Cardinal Health wins new FDA approval for Lymphoseek
Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first … [Read More...] about Cardinal Health wins new FDA approval for Lymphoseek
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos' iDose TR implant contains a novel formulation of travoprost, … [Read More...] about Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its … [Read More...] about ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
Ananda Scientific enrolls first patient in Liquid Structure CBD trial for treating PTSD
Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD. In collaboration with the NYU Grossman School of Medicine, Ananda's clinical trial will evaluate … [Read More...] about Ananda Scientific enrolls first patient in Liquid Structure CBD trial for treating PTSD
BD surpasses 2 billion orders for COVID-19 vaccine injection devices
BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD's latest milestone comes less than six months after the company surpassed 1 million orders … [Read More...] about BD surpasses 2 billion orders for COVID-19 vaccine injection devices
Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for … [Read More...] about Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
Carbon Health acquires Steady Health and its diabetes platform
Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its … [Read More...] about Carbon Health acquires Steady Health and its diabetes platform
Dexcom touts CGM studies, shares data on next-gen G7
Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & … [Read More...] about Dexcom touts CGM studies, shares data on next-gen G7
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous … [Read More...] about Study shows CGMs better at controlling blood sugar in type 2 diabetes
In case you missed it
- Medtronic touts real-world results for MiniMed 780G insulin pump
- FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health
- Lyra inks $135M partnership to expand chronic rhinosinusitis treatment in Asia
- SEC lawsuit accuses RenovaCare of securities fraud
- Noveome Biotherapeutics inks licensing deal for SipNose drug delivery device
- NRx Pharmaceuticals touts Zyesami results, seeks EUA for treating COVID-19
- DarioHealth touts research on digital therapeutics for diabetes patients
- Phillips-Medisize unveils Aria smart autoinjector
- Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor
- Retractable Technologies wins $27M federal contract
- Nanoform, Celanese partner to develop nanoparticle-enabled drug delivery
- NeuroRx completes merger with SPAC, starts trading on Nasdaq
- BD applicators cited in medical kit recall
- UC Riverside researchers tout piezoelectric polymer for drug delivery
- Avalyn Pharma touts study of aerosolized pulmonary fibrosis treatment
Clinical Trials
FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed the proprietary formulation of its selective JAK1/JAK2 inhibitor ruxolitinib for topical application, according to a news release. Currently, the ruxolitinib […]
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients […]
Ananda Scientific enrolls first patient in Liquid Structure CBD trial for treating PTSD
Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD. In collaboration with the NYU Grossman School of Medicine, Ananda’s clinical trial will evaluate Nantheia A1002N5S, an investigational drug that uses cannabidiol (CBD) in Ananda’s proprietary Liquid Structure delivery technology to treat post-traumatic […]
Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system […]
